GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » EBITDA Margin %

VRCDF (Verici Dx) EBITDA Margin % : -28.36% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Verici Dx's EBITDA for the six months ended in Jun. 2024 was $-0.95 Mil. Verici Dx's Revenue for the six months ended in Jun. 2024 was $3.34 Mil. Therefore, Verici Dx's EBITDA margin for the quarter that ended in Jun. 2024 was -28.36%.


Verici Dx EBITDA Margin % Historical Data

The historical data trend for Verici Dx's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx EBITDA Margin % Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - - -777.49

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial - - -25,189.47 -310.87 -28.36

Competitive Comparison of Verici Dx's EBITDA Margin %

For the Diagnostics & Research subindustry, Verici Dx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Verici Dx's EBITDA Margin % falls into.


;
;

Verici Dx EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Verici Dx's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-7.876/1.013
=-777.49 %

Verici Dx's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.947/3.339
=-28.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx  (OTCPK:VRCDF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Verici Dx EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Verici Dx's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines